In the rapidly advancing field of peptide-based drug discovery, few compounds have captured the attention of researchers and industry observers quite like the PN 235 peptide. As someone who closely follows Icotrokinra (JNJ-2113, formerly PN-235), is the first targeted oral peptide designed to selectively block the IL-23 receptor,which underpins the the evolution of specialized chemical entities, I have observed how this specific molecule—later identified as JNJ-2113 and now known by its generic name, Icotrokinra—represents a significant milestone in oral delivery technology.
The Scientific Significance of PN 235
When we discuss PN 235, we are looking at a milestone in molecular engineering. Historically, the challenge with peptides has always been their stability and bioavailability when administered orally. The development of PN-235—a macrocyclic peptide—changed the landscape by demonstrating that it is possible to design molecules that remain stable within the gastrointestinal tract while maintaining high target specificity.
The primary function of this molecule is to selectively block the interleukin (IL)-23 receptor. By interacting with this specific pathway, the molecule aims to selectively inhibit interleukin (IL)-23 signaling, which is a critical mechanism in various immune-mediated conditions. Unlike earlier iterations such as PTG-200—where PTG-200 is an oral peptide interleukin-23 receptor (IL-23R) antagonist—the transition to the JNJ-77242113 (formerly PN-235) pla Protagonist Therapeutics Announces First Subject Dosed tform marked a substantial increase in potency.
From Discovery to Clinical Progress
My interest in this field began when PN-235 has shown promise in earlier stages of testing, particularly during its Phase 1 trials. Witnessing the progression of this entity has been a masterclass in pharmaceutical development. For those tracking the timing of icotrokinra (JNJ-2113, formerly PN-235), it is clear that the collaboration between Protagonist Therapeutics and Janssen has been instrumental.
The data surrounding JNJ-2113 (formerly PN-235) has been consistently robust. During the early development phases, it was widely discussed that PN-235 is expected to advance into Phase 2 studies in psoriasis, a goal that was successfully met and surpassed. This progression highlights the viability of macrocyclic structures in creating "first-in-class" therapeutics.
Comparative Analysis: PN Series a May 15, 2026 — Icotrokinra is a first-in-class, orally bioavailable macrocyclic peptide antagonist of IL-23R that gained FDA approval for nd Beyond
It is helpful to distinguish between the different assets in this pipeline to appreciate the innovation. While PN-235 focused on the IL-23 pathway, newer developments like PN-881 have emerged to target the IL-17 pathway. This modular approach to drug design—using a flexible, synthetic backbone—allows researchers to pivot between targets with high precision.
When reviewing the 23 by S Berger · 2024 · Cited by 86 — Oral peptides are in development for psoriasis and IBD, targeting IL-23R (PN-235 Connecting two hIL-17A-binding domains with a flexible 5 series, one must acknowledge the technical precision required to stabilize these chains. The PN designation has become synonymous with high-quality, orally bioavailable research tools. Whether discussing the structural nuances of the JNJ-77242113 (formerly PN-235) or the broader implications for peptides in the future, the industry is clearly moving toward more targeted, patient-friendly delivery methods.
Final Reflections
As an observer of these advancements, the trajectory of the PN 235 peptide serves as a testament to the power of targeted molecular design. By focusing on the IL-23 receptor, this class of molecules has provided invaluable insights into how we can modulate biological pathways without the need for invasive delivery methods.
For those interested in the future of this s Protagonist Introduces Oral Peptide IL-17 Antagonist PN-881 pace, keeping an eye on the transition from JNJ-2113 (formerly PN-235) to its current clinical status provi ❗️ICYMI: Protagonist Therapeutics recently announced that PN-881 has been identified as a development candidate for immune-mediated skin des a clear roadmap of how rigorous testing and innovative chemistry can redefine the standards of modern biotechnology. The success of this molec Areas of Focus ule continues to pave the way for a new generation of oral therapeutic candidates.